1. Market Research
  2. > Immunotope, Inc. - Product Pipeline Review - 2013

Immunotope, Inc. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 25 pages

Immunotope, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “Immunotope, Inc. - Product Pipeline Review - 2013” provides data on the Immunotope, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Immunotope, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Immunotope, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Immunotope, Inc. - Brief Immunotope, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Immunotope, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Immunotope, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Immunotope, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Immunotope, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Immunotope, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Immunotope, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Immunotope, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Immunotope, Inc. and identify potential opportunities in those areas.

Table Of Contents

Immunotope, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Immunotope, Inc. Snapshot 4
Immunotope, Inc. Overview 4
Key Information 4
Key Facts 4
Immunotope, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Immunotope, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Out-Licensed Products 9
Out-Licensed Products/Combination Treatment Modalities 10
Immunotope, Inc. - Pipeline Products Glance 11
Immunotope, Inc. - Clinical Stage Pipeline Products 11
Phase I Products/Combination Treatment Modalities 11
Immunotope, Inc. - Early Stage Pipeline Products 12
Preclinical Products/Combination Treatment Modalities 12
Discovery Products/Combination Treatment Modalities 13
Immunotope, Inc. - Drug Profiles 14
IMT-1012 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Vaccine For Dengue 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Vaccine For Infectious Diseases 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
Vaccine For Influenza 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
Immunotope, Inc. - Pipeline Analysis 18
Immunotope, Inc. - Pipeline Products by Therapeutic Class 18
Immunotope, Inc. - Pipeline Products by Target 20
Immunotope, Inc. - Pipeline Products by Route of Administration 21
Immunotope, Inc. - Pipeline Products by Molecule Type 22
Immunotope, Inc. - Locations And Subsidiaries 23
Head Office 23
Appendix 24
Methodology 24
Coverage 24
Secondary Research 24
Primary Research 24
Expert Panel Validation 24
Contact Us 25
Disclaimer 25



List of Tables

Immunotope, Inc., Key Information 4
Immunotope, Inc., Key Facts 4
Immunotope, Inc. - Pipeline by Indication, 2013 6
Immunotope, Inc. - Pipeline by Stage of Development, 2013 7
Immunotope, Inc. - Monotherapy Products in Pipeline, 2013 8
Immunotope, Inc. - Out-Licensed Products in Pipeline, 2013 9
Immunotope, Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2013 10
Immunotope, Inc. - Phase I, 2013 11
Immunotope, Inc. - Preclinical, 2013 12
Immunotope, Inc. - Discovery, 2013 13
Immunotope, Inc. - Pipeline by Therapeutic Class, 2013 19
Immunotope, Inc. - Pipeline by Target, 2013 20
Immunotope, Inc. - Pipeline by Route of Administration, 2013 21
Immunotope, Inc. - Pipeline by Molecule Type, 2013 22



List of Figures

Immunotope, Inc. - Pipeline by Top 10 Indication, 2013 6
Immunotope, Inc. - Pipeline by Stage of Development, 2013 7
Immunotope, Inc. - Monotherapy Products in Pipeline, 2013 8
Immunotope, Inc. - Pipeline by Top 10 Therapeutic Class, 2013 18
Immunotope, Inc. - Pipeline by Top 10 Target, 2013 20
Immunotope, Inc. - Pipeline by Top 10 Route of Administration, 2013 21
Immunotope, Inc. - Pipeline by Top 10 Molecule Type, 2013 22



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.